| Literature DB >> 33941626 |
Vanja Milosevic1,2, Aimee Linkens3,4, Bjorn Winkens5, Kim P G M Hurkens6, Dennis Wong1, Brigit P C van Oijen1, Hugo M van der Kuy7, Carlota Mestres-Gonzalvo8.
Abstract
OBJECTIVES: To develop (part I) and validate (part II) an electronic fall risk clinical rule (CR) to identify nursing home residents (NH-residents) at risk for a fall incident.Entities:
Keywords: clinical pharmacology; general medicine (see internal medicine); geriatric medicine
Mesh:
Year: 2021 PMID: 33941626 PMCID: PMC8098923 DOI: 10.1136/bmjopen-2020-042941
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1Inclusion of nursing home residents Zuyderland Medical Centre in part I of the study. *Model I is at the reference date (=day of the fall incident), model II is 3 days prior to the reference date and model III is 5 days prior to the reference date.
Resident characteristics in part I of the study
| Model I (day 0) | Model II (day −3) | Model III (day −5) | |||||||
| Faller (n=412) | Non-faller (n=412) | Total (n=824) | Faller (n=409) | Non-faller (n=407) | Total (n=816) | Faller (n=407) | Non-faller (n=405) | Total (n=812) | |
| Mean age ±SD (y) | 83.91±6.87 | 80.96±9.59 | 82.43±8.46 | 83.89±6.86 | 81.05±9.49 | 82.47±8.39 | 83.90±6.88 | 81.13±9.42 | 82.52±8.36 |
| Male | 151 (36.7%) | 101 (24.5%) | 252 (30.6%) | 149 (36.4%) | 97 (23.8%) | 246 (30.1%) | 148 (36.4%) | 95 (23.5%) | 243 (29.9%) |
| Female | 261 (63.3%) | 311 (75.5%) | 572 (69.4%) | 260 (63.6%) | 310 (76.2%) | 570 (69,9%) | 259 (63.6%) | 310 (76.5%) | 569 (70.1%) |
SD, Standard Deviation; y, years.
Fall risk variables
| Variable | Description |
|
| |
| ATCunique | Number of unique ATC codes |
| ATCunique≥5 | Presence of 5 or more unique ATC codes (yes=1, no=0) |
| ATCunique 0–5 | Presence of 0–5 unique ATC codes (yes=1, no=0) |
| ATCunique 5–10 | Presence of 5–10 unique ATC codes (yes=1, no=0) |
| ATCunique10 - 15 | Presence of 10–15 unique ATC codes (yes=1, no=0) |
| ATCunique≥15 | Presence of 15 or more unique ATC codes (yes=1, no=0) |
|
| |
| Gender | Male/female |
| Age | Age in years |
| Age_c | Age in years, centred |
| Age_c2 | Age in years, centred quadratic term |
|
| |
| A02B | Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) |
| A10 | Drugs used in diabetes |
| C01 | Cardiac therapy |
| C01A | Cardiac glycosides |
| C01B | Antiarrhythmics, classes I and III |
| C01C | Cardiac stimulants excl. cardiac glycosides |
| C01D | Vasodilators used in cardiac diseases |
| C02 | Antihypertensives |
| C03 | Diuretics (cardiovascular system) |
| C04AC | Nicotinic acid and derivatives (peripheral vasodilators) |
| C07 | Beta blocking agents (cardiovascular system) |
| C08 | Calcium channel blockers (cardiovascular system) |
| C09 | Agents acting on the renin-angiotensin system |
| C10 | Lipid modifying agents |
| G04 | Urologicals |
| G04CA | Alpha-adrenoreceptor antagonists (urologicals) |
| M01A | Antiinflammatory and antirheumatic products, non-steroids |
| M03 | Muscle relaxants |
| N02A | Opioids (analgetics) |
| N02B | Other analgesics and antipyretics |
| N03A | Antiepileptics |
| N04 | Anti-Parkinson drugs |
| N04A | Anticholinergic agents (anti-Parkinson drugs) |
| N05A | Antipsychotics |
| N05B | Anxiolytics |
| N05C | Hypnotics and sedatives |
| N06A | Antidepressants |
| N06D | Antidementia drugs |
| N06DA | Anticholinesterases (psychoanaleptics) |
| N07AA | Anticholinesterases (parasympathomimetics) |
| N07C | Antivertigo preparations |
| R01BA | Sympathomimetics (respiratory system) |
| R06A | Antihistamines for systemic use |
| S01ED | Beta blocking agents (ophthalmologicals) |
ATC, Anatomical Therapeutic Chemical.
Fall risk predictive algorithm (CR) for model III (5 days prior to reference day)
| Fall risk predictive CR (model III) in NH-residents: | |
| Fall risk=1/(1+exp(-linear predictor). | |
| Linear predictor=0.7799–0.6802*V1+0.0460*V2- −0.0016*V3+1.6442*V4+0.2664*V5 −0.4763*V6+0.4267*V7+0.2368*V8+0.0001*V9 −0.3780*V10+0.2927*V11 | |
| Predictive fall risk factors: | |
| V1 | Gender (1=male, 2=female) |
| V2 | Age_c=age −82,52 (age centred, linear term) |
| V3 | Age_c2 = (age_c)2 (age centred, quadratic term) |
| V4 | Presence of medicines with ATC code NO6D (yes=1, no=0) |
| V5 | Presence of medicines with ATC code N06A (yes=1, no=0) |
| V6 | Presence of medicines with ATC code N03A (yes=1, no=0) |
| V7 | Presence of medicines with ATC code N05A (yes=1, no=0) |
| V8 | Presence of medicines with ATC code N05C (yes=1, no=0) |
| V9 | Presence of medicines with ATC code G04 (yes=1, no=0) |
| V10 | Presence of medicines with ATC code N02A (yes=1, no=0) |
| V11 | Presence of medicines with ATC code N05B (yes=1, no=0) |
ATC, Anatomical Therapeutic Chemical; CR, clinical rule.
Figure 2ROC curve fall risk predictive clinical rule. ROC, receiver operating characteristics.